Curr Top Microbiol Immunol. 2009;333:109-32. doi: 10.1007/978-3-540-92165-3_5.

Live attenuated vaccines for pandemic influenza.

Source

Laboratory of Infectious Diseases, NIAID, NIH, Building 33, 3E 13C.2, 33 North Drive, MSC 3203, Bethesda, MD 20892-3203, USA.

Abstract

In this chapter, we will review the development of and clinical experience with the currently licensed seasonal live attenuated influenza vaccines (LAIV) and preclinical studies of H5, H7, and H9 live attenuated pandemic influenza vaccine candidates. Vectored vaccine approaches will not be reviewed in this chapter. Experience with seasonal influenza vaccination has demonstrated the safety and efficacy of LAIV in both children and adults; moreover, cross-protection among antigenically distinct viruses within the same subtype may be induced by LAIV. While clinical studies and further characterization of the immunologic response to avian influenza viruses are still needed, the experience with seasonal LAIV underscores the potential of live attenuated vaccines to play an important role in the event of a pandemic.

PMID:: 19768402; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Springer

Medical

Flu - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. [Influenza Other Respi Viruses....]
Review Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.
Ambrose CS, Luke C, Coelingh K. Influenza Other Respi Viruses. 2008 Nov; 2(6):193-202.
Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. [Vaccine. 2006]
Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI. Vaccine. 2006 Nov 17; 24(47-48):6859-66. Epub 2006 Jun 28.
Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). [Influenza Other Respi Viruses....]
Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).
Rudenko L, Desheva J, Korovkin S, Mironov A, Rekstin A, Grigorieva E, Donina S, Gambaryan A, Katlinsky A. Influenza Other Respi Viruses. 2008 Nov; 2(6):203-9.
Review [Tetravaccine--new fundamental approach to prevention of influenza pandemic]. [Zh Mikrobiol Epidemiol Immunob...]
Review [Tetravaccine--new fundamental approach to prevention of influenza pandemic].
Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN. Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug; (4):15-9.
Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. [Vaccine. 2008]
Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y. Vaccine. 2008 Mar 25; 26(14):1742-50. Epub 2008 Feb 13.

See reviews... See all...

Cited by 5 PubMed Central articles

Ferretting out the facts behind the H5N1 controversy. [Bioeng Bugs. 2012]
Ferretting out the facts behind the H5N1 controversy.
Sleator RD. Bioeng Bugs. 2012 May-Jun; 3(3):139-43. Epub 2012 May 1.
H5N1 influenza viruses: facts, not fear. [Proc Natl Acad Sci U S A. 2012]
H5N1 influenza viruses: facts, not fear.
Palese P, Wang TT. Proc Natl Acad Sci U S A. 2012 Feb 14; 109(7):2211-3. Epub 2012 Jan 25.
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. [PLoS One. 2011]
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP.
Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzmán CA, Cox RJ. PLoS One. 2011; 6(11):e26973. Epub 2011 Nov 1.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Live attenuated vaccines for pandemic influenza.
Live attenuated vaccines for pandemic influenza.
Curr Top Microbiol Immunol. 2009 ;333:109-32. doi: 10.1007/978-3-540-92165-3_5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: